CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: C6orf62 (ImmuneEditome ID:81688)

1. Gene summary of enriched editing regions for C6orf62

check button Gene summary
Gene informationGene symbol

C6orf62

Gene ID

81688

GeneSynonymsNbla00237|XTP12|dJ30M3.2
GeneCytomap

6p22.3

GeneTypeprotein-coding
GeneDescriptionuncharacterized protein C6orf62|HBV X-transactivated gene 12 protein|HBV X-transactivated protein 12|HBV XAg-transactivated protein 12
GeneModificationdate20230329
UniprotIDQ9GZU0;A0A024R026
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr6:24710255-24710991:-ENST00000378102.3ENSG00000112308.11C6orf62intronicAluSp,AluJrchr6:24710255-24710991:-.alignment
chr6:24710255-24710991:-ENST00000378119.7ENSG00000112308.11C6orf62intronicAluSp,AluJrchr6:24710255-24710991:-.alignment


Top

2. Tumor-specific enriched editing regions for C6orf62


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for C6orf62


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for C6orf62


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for C6orf62


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr6:24710255-24710991:-BLCAEERNeutrophils1.4981e-030.2376image
ENSG00000112308.11,C6orf62BLCAEAGB_cells_naive3.5418e-030.2145image
chr6:24710255-24710991:-BRCAEERMonocytes2.4931e-030.1284image
ENSG00000112308.11,C6orf62BRCAEAGMonocytes1.7825e-030.1314image
ENSG00000112308.11,C6orf62CESCEAGT_cells_CD4_naive2.5065e-020.2251image
chr6:24710255-24710991:-COADEEREosinophils1.6599e-040.4189image
ENSG00000112308.11,C6orf62COADEAGEosinophils2.4007e-050.4561image
chr6:24710255-24710991:-ESCAEERMast_cells_activated1.1806e-020.2146image
chr6:24710255-24710991:-GBMEERT_cells_CD87.8733e-030.2295image
ENSG00000112308.11,C6orf62GBMEAGT_cells_CD88.0567e-030.2280image
ENSG00000112308.11,C6orf62HNSCEAGT_cells_CD84.8195e-030.2930image
ENSG00000112308.11,C6orf62KIRPEAGNeutrophils1.0759e-030.3801image
chr6:24710255-24710991:-LGGEERNK_cells_activated2.5256e-02-0.1210image
ENSG00000112308.11,C6orf62LGGEAGNK_cells_activated2.1245e-02-0.1245image
ENSG00000112308.11,C6orf62LIHCEAGMacrophages_M22.2566e-020.2193image
chr6:24710255-24710991:-OVEERMast_cells_activated1.4308e-020.1939image
ENSG00000112308.11,C6orf62OVEAGMast_cells_activated4.2954e-020.1545image
ENSG00000112308.11,C6orf62PAADEAGMacrophages_M04.2921e-020.2481image
chr6:24710255-24710991:-PRADEERPlasma_cells5.1301e-03-0.1728image
ENSG00000112308.11,C6orf62PRADEAGPlasma_cells1.8664e-03-0.1902image
ENSG00000112308.11,C6orf62SARCEAGNK_cells_activated7.3807e-030.2938image
ENSG00000112308.11,C6orf62SKCMEAGT_cells_follicular_helper1.8542e-020.1624image
chr6:24710255-24710991:-STADEERT_cells_CD4_memory_activated1.3178e-020.1643image
ENSG00000112308.11,C6orf62STADEAGT_cells_CD89.0918e-030.1698image
chr6:24710255-24710991:-THCAEERDendritic_cells_resting4.5716e-040.2250image
ENSG00000112308.11,C6orf62THCAEAGDendritic_cells_resting1.2853e-030.2062image
ENSG00000112308.11,C6orf62THYMEAGNK_cells_activated2.5688e-030.3987image
chr6:24710255-24710991:-UCECEERDendritic_cells_resting3.1109e-020.3053image
ENSG00000112308.11,C6orf62UCECEAGDendritic_cells_resting2.6404e-020.3108image
ENSG00000112308.11,C6orf62UCSEAGT_cells_CD4_memory_resting9.2304e-030.5536image


Top

6. Enriched editing regions and immune gene sets for C6orf62


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000112308.11,C6orf62BLCAGSVA_HALLMARK_DNA_REPAIREAG1.8392e-04-0.2731image
chr6:24710255-24710991:-BLCAGSVA_HALLMARK_DNA_REPAIREER5.0103e-03-0.2107image
ENSG00000112308.11,C6orf62BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEAG8.3718e-05-0.1650image
chr6:24710255-24710991:-BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEER4.8755e-05-0.1718image
ENSG00000112308.11,C6orf62CESCGSVA_HALLMARK_HYPOXIAEAG1.8759e-02-0.2359image
chr6:24710255-24710991:-COADGSVA_HALLMARK_UV_RESPONSE_UPEER6.1499e-03-0.3116image
ENSG00000112308.11,C6orf62COADGSVA_HALLMARK_UV_RESPONSE_UPEAG7.0067e-04-0.3734image
ENSG00000112308.11,C6orf62ESCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.5758e-02-0.1770image
chr6:24710255-24710991:-GBMGSVA_HALLMARK_MITOTIC_SPINDLEEER1.1130e-02-0.2195image
ENSG00000112308.11,C6orf62GBMGSVA_HALLMARK_MITOTIC_SPINDLEEAG9.3214e-03-0.2238image
ENSG00000112308.11,C6orf62HNSCGSVA_HALLMARK_HYPOXIAEAG4.6449e-02-0.2093image
chr6:24710255-24710991:-KIRCGSVA_HALLMARK_PEROXISOMEEER3.1361e-020.1642image
ENSG00000112308.11,C6orf62KIRPGSVA_HALLMARK_COAGULATIONEAG1.2322e-02-0.2956image
ENSG00000112308.11,C6orf62LAMLGSVA_HALLMARK_BILE_ACID_METABOLISMEAG4.0919e-02-0.2184image
ENSG00000112308.11,C6orf62LGGGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.4700e-02-0.1318image
chr6:24710255-24710991:-LGGGSVA_HALLMARK_MTORC1_SIGNALINGEER2.1521e-02-0.1243image
ENSG00000112308.11,C6orf62LIHCGSVA_HALLMARK_P53_PATHWAYEAG2.9728e-020.2093image
chr6:24710255-24710991:-LUADGSVA_HALLMARK_MTORC1_SIGNALINGEER2.3502e-02-0.1582image
ENSG00000112308.11,C6orf62LUADGSVA_HALLMARK_MTORC1_SIGNALINGEAG4.3500e-02-0.1369image
ENSG00000112308.11,C6orf62LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.2941e-030.2078image
ENSG00000112308.11,C6orf62MESOGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.0747e-02-0.4319image
ENSG00000112308.11,C6orf62OVGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG3.4912e-020.1610image
chr6:24710255-24710991:-OVGSVA_HALLMARK_MTORC1_SIGNALINGEER4.3159e-020.1606image
chr6:24710255-24710991:-PAADGSVA_HALLMARK_GLYCOLYSISEER7.2932e-030.3274image
ENSG00000112308.11,C6orf62PAADGSVA_HALLMARK_GLYCOLYSISEAG6.3543e-030.3302image
ENSG00000112308.11,C6orf62PCPGGSVA_HALLMARK_HYPOXIAEAG2.1476e-02-0.3095image
chr6:24710255-24710991:-PRADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.2879e-02-0.1538image
ENSG00000112308.11,C6orf62PRADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG4.2946e-03-0.1749image
ENSG00000112308.11,C6orf62READGSVA_HALLMARK_SPERMATOGENESISEAG2.1861e-02-0.4476image
ENSG00000112308.11,C6orf62SARCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG4.6746e-02-0.2203image
ENSG00000112308.11,C6orf62SKCMGSVA_HALLMARK_COAGULATIONEAG5.7505e-03-0.1900image
ENSG00000112308.11,C6orf62STADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.5675e-030.1958image
chr6:24710255-24710991:-STADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER5.7222e-030.1829image
ENSG00000112308.11,C6orf62THCAGSVA_HALLMARK_UV_RESPONSE_UPEAG6.5245e-03-0.1748image
chr6:24710255-24710991:-THCAGSVA_HALLMARK_UV_RESPONSE_UPEER3.4621e-02-0.1367image
ENSG00000112308.11,C6orf62THYMGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG4.9469e-030.3737image
ENSG00000112308.11,C6orf62UCECGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG2.6221e-020.3112image
chr6:24710255-24710991:-UCECGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.0516e-020.3588image
ENSG00000112308.11,C6orf62UCSGSVA_HALLMARK_APICAL_JUNCTIONEAG6.0339e-03-0.5783image


Top

7. Enriched editing regions and drugs for C6orf62


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr6:24710255-24710991:-BLCAMidostaurinEER9.3622e-05-0.2902image
ENSG00000112308.11,C6orf62BLCAA.443654EAG4.5797e-040.2564image
ENSG00000112308.11,C6orf62BRCACCT007093EAG3.4929e-06-0.1941image
chr6:24710255-24710991:-BRCACCT007093EER2.0065e-05-0.1803image
ENSG00000112308.11,C6orf62CESCABT.263EAG2.1101e-020.2316image
ENSG00000112308.11,C6orf62CHOLDMOGEAG1.8245e-020.4682image
ENSG00000112308.11,C6orf62COADLFM.A13EAG4.1056e-03-0.3195image
chr6:24710255-24710991:-COADLFM.A13EER1.1905e-02-0.2871image
ENSG00000112308.11,C6orf62ESCAKU.55933EAG2.2726e-02-0.1924image
chr6:24710255-24710991:-GBMJNK.Inhibitor.VIIIEER1.9602e-030.2661image
ENSG00000112308.11,C6orf62GBMJNK.Inhibitor.VIIIEAG1.9322e-030.2655image
ENSG00000112308.11,C6orf62HNSCGNF.2EAG3.1709e-020.2254image
ENSG00000112308.11,C6orf62KIRCAMG.706EAG4.5622e-02-0.1518image
chr6:24710255-24710991:-KIRCEtoposideEER3.2937e-020.1627image
ENSG00000112308.11,C6orf62KIRPDoxorubicinEAG5.2729e-03-0.3277image
ENSG00000112308.11,C6orf62LAMLAKT.inhibitor.VIIIEAG2.9539e-02-0.2321image
ENSG00000112308.11,C6orf62LGGBIRB.0796EAG3.7495e-02-0.1126image
ENSG00000112308.11,C6orf62LIHCCamptothecinEAG1.3594e-020.2368image
chr6:24710255-24710991:-LUADDMOGEER7.7510e-030.1855image
ENSG00000112308.11,C6orf62LUADAZD6244EAG3.0316e-02-0.1467image
ENSG00000112308.11,C6orf62LUSCDMOGEAG3.4234e-03-0.1894image
ENSG00000112308.11,C6orf62MESOMG.132EAG2.6731e-040.5865image
chr6:24710255-24710991:-OVCisplatinEER7.9192e-030.2099image
ENSG00000112308.11,C6orf62OVGefitinibEAG1.6843e-03-0.2378image
ENSG00000112308.11,C6orf62PAADFTI.277EAG5.7725e-03-0.3338image
chr6:24710255-24710991:-PAADFTI.277EER7.0397e-03-0.3287image
ENSG00000112308.11,C6orf62PCPGLenalidomideEAG1.0034e-02-0.3444image
chr6:24710255-24710991:-PRADJNK.9LEER1.3705e-020.1524image
ENSG00000112308.11,C6orf62PRADJNK.9LEAG7.0205e-030.1652image
ENSG00000112308.11,C6orf62READCI.1040EAG9.6376e-04-0.6089image
ENSG00000112308.11,C6orf62SARCCyclopamineEAG2.5228e-02-0.2471image
ENSG00000112308.11,C6orf62SKCMKIN001.135EAG3.3297e-030.2017image
ENSG00000112308.11,C6orf62STADBMS.509744EAG7.8541e-03-0.1730image
chr6:24710255-24710991:-STADImatinibEER5.1259e-030.1852image
chr6:24710255-24710991:-THCABortezomibEER3.6605e-030.1873image
ENSG00000112308.11,C6orf62THCABortezomibEAG4.7822e-030.1812image
ENSG00000112308.11,C6orf62THYMCMKEAG1.7506e-030.4125image
ENSG00000112308.11,C6orf62UCECCGP.60474EAG1.2916e-02-0.3459image
chr6:24710255-24710991:-UCECA.770041EER2.6350e-02-0.3141image
ENSG00000112308.11,C6orf62UCSCHIR.99021EAG1.2097e-030.6571image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType